Moreover, biomarkers of sensitivity to CX-5461 in ovarian cancer models include BRCA-mutated and MYC targets gene expression signatures that were found to be enriched in a subset of primary and relapsed ovarian cancer.43 As MYC is a master regulator of ribosome biogenesis, MYC-driven Pol I transcription and/or MYC-driven global transcription and replication stress may underlie sensitivity to CX-5461. The gene discussed is MYC; the disease is ovarian cancer.